Nemaura Plans To Launch Body-Worn Continuous Temperature Monitor (CTM) to Track Fever Caused by Viral Infections such as COVI...
April 01 2020 - 8:03AM
Business Wire
BEAT® platform is planned to be extended to conditions
requiring continuous temperature monitoring including viral
infections and poor blood circulation to feet in persons with
diabetes
Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the
“Company”), a medical technology company focused on developing
micro-systems-based wearable diagnostic devices and currently
commercializing sugarBEAT®, its non-invasive and flexible
continuous glucose monitor (“CGM”), announced plans for a new
product line by seeking to immediately repurpose sugarBEAT® as a
CTM since its inbuilt temperature sensor is capable of continuously
tracking body temperature through the skin. Nemaura is considering
various options to expedite the launch of a CTM, including
potential partnerships and direct to consumer sales.
CTM’s have been recognised as potentially having a key role to
play in battling COVID-19, with Google’s Verily announcing plans to
develop a small body worn temperature patch that transmits data to
a phone application to provide timely notification of fever and
support earlier diagnosis and treatment of viral infections like
the flu or coronavirus1.Nemaura’s body worn skin patch designed to
monitor glucose levels on the skin at 5 minute intervals also
contains a thermistor which measures skin temperature as an
integral part of the device, and we believe that the device could
easily be repurposed for this standalone function. The CGM device
is CE approved in Europe and in commercial production in the
UK.
“We see a significant commercial opportunity to utilise our
BEAT® platform technology specifically for CTM purposes with data
being automatically sent by low energy Bluetooth to a mobile phone
app from which it can then be reviewed by the user and/or sent to a
family member or caregiver. We believe that there are parallels
between family members and caregivers remotely monitoring glucose
fluctuations in a person, and monitoring fever caused by viral
infections, providing a means of remote tracking and intervention.
In the current climate we see this as an opportunity to contribute
to general wellbeing and patient management” stated Dr. Faz
Chowdhury, Nemaura’s CEO.
Several diseases including COVID-19 are characterised by fever
(an increase in body temperature) meaning that temperature
monitoring can be a vital tool in the detection of such conditions
and consequently a potential means of containing the spread of the
disease through early self-isolation. Measuring body temperature on
a continuous basis may also be used to track the course of a
disease and so allow physicians to analyse the effectiveness of
treatments and thus pro-actively adapt to improve outcomes.
Dr. Chowdhury further stated “body temperature can vary
depending on the age of the person, their level of (recent)
physical activity, the time the measurement is taken and
importantly where on the body the temperature is taken. For this
reason, I believe that the ability to track the temperature
continuously over time and measure the rate at which it is rising
or falling would be a superior form of monitoring a person than
sporadic measurements taken using a more traditional
thermometer.”
We believe that multiple other future uses are foreseen for a
CTM including tracking ovulation to improve the chances of
conception and for predicting/preventing diabetes related foot
complications such as ulcers which can eventually lead to
amputation if not detected early enough, whereby poor blood
circulation can be rapidly detected by continuous temperature
monitoring of the affected region. Further details are provided in
a publication on the company’s website:
https://nemauramedical.com/wp-content/uploads/2020/04/NMRD-Temp-Monitoring-USA-March-2020-FINAL-V1.1.pdf
Nemaura is establishing the regulatory framework for launching
the CTM in a number of worldwide territories, including initial
immediate use to provide qualitative indications without disease
diagnosis.
-
https://www.blog.google/inside-google/company-announcements/coronavirus-covid19-response/
About Nemaura Medical, Inc.:
Nemaura Medical Inc. (NMRD) is a medical technology company
developing micro-systems-based wearable diagnostic devices and
currently commercializing sugarBEAT™, and proBEAT™. sugarBEAT® is a
Class IIb CE marked non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse and
prevent the onset of diabetes. People with diabetes who take
insulin can also adjunctively use sugarBEAT® for insulin dosage
purposes when calibrated by a finger stick reading. proBEAT™
comprises a prescription free non-invasive glucose monitor and a
digital healthcare subscription service planned to be launched in
the US as a general wellness product.
For more information visit: www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements: The statements in this press release that are not
historical facts may constitute forward-looking statements that are
based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of sugarBEAT® as a CGM / CTM in the US, risks related to
regulatory approvals and the success of Nemaura’s ongoing studies,
including the safety and efficacy of Nemaura’s sugarBEAT® system,
the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
sugarBEAT®, the availability of substantial additional equity or
debt capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
sugarBEAT®. There can be no assurance that the company will be able
to reach a part of or any of the global market for CGM or CTM with
its products/services and there can be no assurance that the
foregoing repurposing can occur as planned.. These and other risks
and uncertainties are identified and described in more detail in
Nemaura’s filings with the United States Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the most recently completed fiscal year, its
Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200401005377/en/
Investor Contact: Dave Gentry, CEO RedChip Companies
Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498
dave@redchip.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024